Mitral valve repair with the Colvin-Galloway Future Band

BACKGROUND: A new annuloplasty device, the Colvin-Galloway Future Band, has been developed to allow simple and safe mitral valve repair surgery. Here we report its clinical use and the clinical results after a short-term, 2-year follow-up. METHODS: We assessed the performance of this new device in 40 consecutive patients (55% male; mean age, 68.3 +/- 8.1 years) who were operated on for mitral valve incompetence between 2001 and 2002. Ninety percent of these patients had associated surgical procedures. Clinical and echocardiographic assessment was performed perioperatively and at a mean follow-up of 16.5 +/- 5.7 months (range, 6 to 25 months) in all patients (100%), permitting analysis of 55 patient-years. RESULTS: Thirty-eight patients survived surgery, resulting in an overall early mortality of 5.0%. There were four noncardiac-related late deaths, resulting in an overall late mortality of 10.0%. Perioperative echocardiography showed no incidences of systolic anterior movement at the time of discharge from the hospital and satisfactory mitral repair results in 36 (95%) patients. At the time of the 2-year follow-up, echocardiography showed satisfactory mitral valve function in all but 2 patients (94%) and a significant postoperative ventricular remodeling: the left ventricular end-diastolic diameter decreased from 64.5 +/- 6.2 mm preoperatively to 50.4 +/- 9.5 mm postoperatively (p < 0.1). At the time of follow-up, 29 (90.6%) patients were in New York Heart Association functional class I or II, all of them describing their quality of life as "significantly improved" if compared with their preoperative status. There were no late reoperations and no thromboembolic, bleeding, or other complications. CONCLUSIONS: The clinical results of the Colvin-Galloway Future Band in this short-term follow-up of patients undergoing complex mitral valve repair seem to be promising.     

Mitral stenosis after mitral valve repair for non-rheumatic mitral regurgitation

BACKGROUND: Mitral stenosis after mitral valve repair for non-rheumatic mitral regurgitation is rare. METHODS: From 1990 to 1999, 478 patients had mitral valve repair for myxomatous and 40 patients had mitral valve repair for ischemic mitral regurgitation. The Carpentier annuloplasty ring (Edwards Lifesciences, Irvine, CA) was used in 72 patients, the Duran ring (Medtronic, Minneapolis, MN) in 152, a posterior band in 221 and no ring or band in 73 patients. RESULTS: Four patients developed mitral stenosis late after mitral valve repair: 2 for myxomatous disease and 2 for ischemic mitral regurgitation. All 4 patients had Duran annuloplasty rings (sizes 25 to 31). The diagnosis of mitral stenosis was made by Doppler echocardiography. The mitral valve area in these 4 patients decreased from 2.7 cm2 (range, 2.3 to 3.2 cm2) early postoperatively to 0.85 cm2 (0.4 to 1.2 cm2) after a mean follow-up of 66 months (range, 38 to 110 months). Three patients had mitral valve replacement and the etiology of the mitral stenosis was the same in all patients (ie, pannus overgrowth on the annuloplasty ring with extension onto both leaflets rendering them stiff and immobile). The fourth patient had a mitral valve area of 1.2 cm2, which was mildly symptomatic with normal pulmonary artery pressure, and this patient has not had reoperation. CONCLUSIONS: Mitral stenosis may develop after mitral valve repair for myxomatous disease or ischemic mitral regurgitation when a Duran ring is used for annuloplasty. The stenosis is caused by pannus on the annuloplasty ring with extension onto the leaflets.     

Mitral and tricuspid valve repair in patients with previous mediastinal radiation therapy

Background

The purpose of this study was to evaluate outcomes of mitral and tricuspid valve repair after mediastinal radiation therapy.

Methods

From 1976 to 2001, 22 patients (mean age 61 ± 14 years) underwent mitral (n = 14), tricuspid (n = 6), or both (n = 2) valve repairs 15 ± 9 years after mediastinal radiation therapy. Concomitant procedures included coronary artery bypass graft, 11 patients; valve replacement, 6 patients (4 aortic, 3 mitral, 1 tricuspid, and 1 pulmonary); and pericardiectomy, 4 patients.

Results

Total follow-up was 82.5 patient-years (mean 3.7 ± 3.3 years). Early mortality was 3 patients. There were 7 late deaths, 4 of which were of cardiovascular origin. Of the 19 early survivors, 2 required subsequent valve replacements, and 1 required cardiac transplantation 3.4 ± 2.8 years after valve repair. One patient died after reoperation. In 4 patients who did not undergo reoperation, echocardiographic examinations showed progressive deterioration of their repaired valve function. Overall survival, freedom from cardiac death, and freedom from valve reoperation or cardiac transplantation at 5 years for early survivors was 66%, 85%, and 88%, respectively. New York Heart Association functional class at follow-up was I or II in 8 of the 12 late survivors.

Conclusions

Functional status was good in two-thirds of late survivors. However, severe dysfunction of the repaired valve developed in 32% of early survivors and 16% required further surgery. Valve repair is technically feasible in selected patients after mediastinal radiation therapy; however, the limited durability of repairs after mediastinal radiation in this series suggests that valve replacement might be preferable.     

Mitral valve repair in a 55-year-old man with left lung agenesis

We report on a 55-year-old man who was diagnosed with agenesis of the left lung in childhood. He was essentially asymptomatic until he was 53 years of age, when he became symptomatic with exertional dyspnea due to severe mitral regurgitation. We performed mitral valve repair using a median sternotomy incision approach.     

Mitral valve repair and septal myectomy for hypertrophic obstructive cardiomyopathy

Combined mitral valve repair using the sliding leaflet technique and septal myectomy were employed to successfully treat left ventricular outflow tract (LVOT) obstruction and mitral regurgitation due to hypertrophic obstructive cardiomyopathy (HOCM). A 46-year-old man was diagnosed with HOCM along with congestive heart failure and was treated medically. These symptoms, however, were resistant to medical treatments with a beta-blocker, a Ca-antagonist, and disopyramide, and he was referred to our hospital for surgery. Doppler echocardiography demonstrated an LVOT obstruction at rest with a peak pressure gradient of 138 mmHg. The interventricular septum thickness was 14 mm. Mitral regurgitation of 3+ with severe SAM was also observed. Temporary dual chamber pacing was tried without significant improvement. Following these examinations, the patient underwent surgery. A transaortic septal myotomy-myectomy was performed first, and the mitral valve was then approached through the left atrium. Mitral valve repair was performed with the sliding leaflet technique to reduce the height of the posterior leaflet from 2 cm to 1 cm. Postpump transesophageal echocardiography revealed no MR and a peak LVOT gradient of 15 mmHg. The patient recovered well except for a residual mild SAM, and MR2+. We therefore concluded that this surgical approach might provide results which are superior to those of myectomy alone.     

Mitral valve aneurysm with infective endocarditis

A case of mitral valve aneurysm associated with infective endocarditis is reported. Two-dimensional echocardiography revealed a saccular structure in the anterior leaflet that bulged into the left atrium throughout the cardiac cycle. During operation, the vegetation on the commissure of the right and left aortic leaflet and a 3-mm perforation on the noncoronary leaflet were found. The mitral valve and aortic valve were replaced with mechanical prosthesis. Pathology of the excised valves showed inflammation. For this patient, we considered that the infected aortic regurgitant jet striking the ventricular surface of the anterior mitral leaflet could be the mechanism of the leaflet aneurysm.     

Mitral valve surgery in non-ischemic cardiomyopathy

Dilated cardiomyopathy is a disorder of the cardiac muscle in which myocyte cytoskeletal weakness leads to ventricular dilatation and congestive cardiac failure. Most commonly, the etiology of non-ischemic cardiomyopathy is unknown (idiopathic) and, in our practice, the second most common cause is advanced valvular heart disease. Functional mitral valve regurgitation occurs in up to 40% of patients with heart failure due to dilated cardiomyopathy and contributes to a vicious cycle of volume overload, further left ventricular dilatation, and worsening mitral valve regurgitation and heart failure. Surgical management of mitral valve regurgitation in dilated cardiomyopathy may carry a high risk and can be very challenging. However, operative risk is mitigated by continued vigorous medical management and judicious perioperative care. For example, at our Clinic, mortality for mitral valve repair or replacement in 43 patients with non-ischemic cardiomyopathy having operation between 1993 and 2002 was 2.3%. Additional procedures to reverse cardiac remodeling have not proven to be uniformly successful and continue to undergo scientific scrutiny. Clinical outcome of mitral valve surgery in non-ischemic dilated cardiomyopathy compares well with cardiac transplantation in the early-to-intermediate term, but the long-term results are less satisfactory. For our patients having mitral valve repair, the 1-, 3-, and 5-year survivorships were 84%, 80% and 33%. Evolving technology and research that focus on methods of altering or reversing cardiomyopathy; e.g., cell transplant, may have significant impact on the future management of this debilitating illness.